Citigroup Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $105
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citigroup analyst Eric Joseph maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $108 to $105.
Citigroup analyst Eric Joseph maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $108 to $105.
